Management of Stomach Ulcers

First-line Pharmacological Treatment

The World Journal of Emergency Surgery recommends starting PPI therapy as soon as possible after diagnosis, with a typical dose of 20-40mg once daily, for 6-8 weeks to allow complete mucosal healing 1
For bleeding ulcers, high-dose PPI therapy is recommended, with an 80mg bolus followed by 8mg/hour continuous infusion for 72 hours, according to the World Journal of Emergency Surgery 2

Helicobacter pylori Eradication

The World Journal of Emergency Surgery suggests testing all patients with gastric ulcers for H. pylori infection, and confirming eradication after treatment completion 1

NSAID-Associated Ulcers

The American College of Gastroenterology recommends discontinuing NSAID therapy when possible, and maintaining PPI therapy long-term if NSAID therapy must continue, as stated in the World Journal of Emergency Surgery 3

Management of Complications

The World Journal of Emergency Surgery recommends endoscopy as the first-line treatment for diagnosis and management of bleeding ulcers, with pre-endoscopy erythromycin improving visualization and reducing the need for repeat endoscopy 4, 2

Common Pitfalls and Caveats

The World Journal of Emergency Surgery warns that failure to test for H. pylori can lead to recurrence rates of 40-50% over 10 years, and that PPIs may reduce absorption of medications requiring an acidic environment 1, 3
The World Journal of Emergency Surgery also recommends that proton pump inhibitors should not replace urgent endoscopy in patients with active bleeding 1

Management of Peptic Ulcer Disease

Pharmacological Treatment

The World Journal of Emergency Surgery recommends that for bleeding peptic ulcers with high-risk stigmata after endoscopic hemostasis, administer 80 mg PPI bolus followed by 8 mg/hour continuous infusion for 72 hours, followed by standard oral PPI therapy for 6-8 weeks 5
The World Journal of Emergency Surgery suggests that PPI therapy should not replace urgent endoscopy in patients with active bleeding, and pre-endoscopy erythromycin improves visualization and reduces need for repeat endoscopy 6

Alternative Therapies

The American Gastroenterological Association, as reported in Gastroenterology, advises that potassium-competitive acid blockers (P-CABs) like vonoprazan should NOT be used as first-line therapy due to higher costs, limited availability, and less robust long-term safety data compared to PPIs 7, 8

Long-Term Management

The World Journal of Emergency Surgery recommends continuing PPI therapy long-term only in specific populations, such as chronic NSAID users who cannot discontinue, and patients with recurrent ulcers despite H. pylori eradication 5

Management of Peptic Ulcer Disease with H. pylori Infection

H. pylori Testing and Eradication

The World Journal of Emergency Surgery recommends standard triple therapy for 14 days for H. pylori eradication, consisting of a PPI standard dose twice daily, clarithromycin 500mg twice daily, and amoxicillin 1000mg twice daily (or metronidazole 500mg twice daily), for patients with low clarithromycin resistance 9
For patients with high clarithromycin resistance, the World Journal of Emergency Surgery suggests sequential therapy for 10 days, with days 1-5 consisting of a PPI standard dose twice daily and amoxicillin 1000mg twice daily, and days 6-10 consisting of a PPI standard dose twice daily, clarithromycin 500mg twice daily, and metronidazole 500mg twice daily 9
If first-line therapy fails, the World Journal of Emergency Surgery recommends 10-day levofloxacin-amoxicillin triple therapy, consisting of a PPI standard dose twice daily, levofloxacin 500mg once daily (or 250mg twice daily), and amoxicillin 1000mg twice daily 9

Approach to Managing Peptic Ulcer Disease

Initial Assessment and Risk Stratification

For patients without alarm features and age <60 years, the American Gastroenterological Association recommends proceeding with the test-and-treat strategy rather than immediate endoscopy, with a strength of evidence based on studies from 2002 10

Pharmacological Management

The American Gastroenterological Association advises against using P-CABs (vonoprazan) as first-line therapy due to higher costs, limited availability, and less robust long-term safety data compared to PPIs, with evidence from 2024 11
Discontinuing NSAID therapy whenever possible heals 95% of ulcers and reduces recurrence from 40% to 9%, and if NSAIDs cannot be discontinued, switching to selective COX-2 inhibitor (celecoxib) with lower gastric toxicity and maintaining long-term PPI therapy is recommended, based on guidelines from the American Gastroenterological Association 11

Management of Peptic Ulcer Disease with PPI Therapy

Initial Pharmacological Treatment

The American College of Physicians recommends that after the initial healing period, patients be discharged with a prescription for single daily-dose oral PPI for a duration dictated by the underlying etiology 12
Most patients who undergo endoscopic hemostasis for high-risk stigmata should be hospitalized for at least 72 hours, as 60-76% of rebleeding episodes occur within this timeframe, according to the American College of Gastroenterology 12

Long-Term Management

For patients requiring continuous NSAID therapy, long-term PPI therapy may be necessary for secondary prophylaxis, as recommended by the American College of Rheumatology 12

Treatment of Peptic Ulcer Disease

Initial Diagnostic and Treatment Approach

The American Gastroenterological Association recommends testing all patients with peptic ulcer disease for H. pylori infection using noninvasive methods (urea breath test or stool antigen test preferred over serology) 13
The American Gastroenterological Association notes that tests for H. pylori have increased false-negative rates during acute bleeding episodes, so repeat testing outside the acute context if initial results are negative 13

H. pylori Eradication Regimens

The American Gastroenterological Association suggests that documenting H. pylori eradication after treatment completion is crucial to ensure successful therapy, as eradication reduces ulcer recurrence from 50-60% to 0-2% 13

NSAID-Associated Ulcers

The American Gastroenterological Association recommends discontinuing all NSAIDs and aspirin immediately when peptic ulcer is diagnosed, as this heals 95% of ulcers and reduces recurrence from 40% to 9% 14
The American College of Gastroenterology suggests that test for and eradicate H. pylori if present, as eradication in NSAID users reduces peptic ulcer likelihood by 50% 15, 14
The American College of Gastroenterology advises that if NSAIDs must be continued for valid medical reasons, switch to a selective COX-2 inhibitor (celecoxib) or lower-risk nsNSAID (ibuprofen) combined with PPI therapy 15, 14

Special Considerations

The American Gastroenterological Association recommends against using Potassium-Competitive Acid Blockers (P-CABs) as first-line therapy for peptic ulcer disease due to higher costs, limited availability, and less robust long-term safety data compared to PPIs 16
The American Heart Association notes that combining PPI with aspirin reduces GI bleeding risk while maintaining cardiovascular benefits 17

Pantoprazole BID Dosing for High-Risk Bleeding Ulcers

Initial Management and Transition to Oral BID Dosing

For patients with bleeding ulcers at high risk for rebleeding who have undergone endoscopic therapy, pantoprazole 40 mg twice daily should be used for 11 days (days 4-14) after completing 3 days of high-dose intravenous PPI therapy, followed by once-daily dosing, as recommended by the American College of Physicians, with a strength of evidence supported by multiple citations 18, 19, 20
Switching to pantoprazole 40 mg twice daily for days 4-14 reduces rebleeding risk by 63% compared to once-daily dosing (RR 0.37, CI 0.19-0.73) in high-risk patients who had undergone successful endoscopic therapy, according to the American College of Gastroenterology 18, 19, 20

Subsequent Maintenance Dosing

After completing 14 days total (3 days IV + 11 days BID oral), continue pantoprazole 40 mg once daily, as recommended by the American College of Physicians, with a strength of evidence supported by multiple citations 18, 19, 20
The American College of Gastroenterology recommends that the total duration of pantoprazole therapy depends on ulcer etiology, with BID dosing specifically reserved for high-risk bleeding ulcers post-endoscopy, according to the American College of Gastroenterology 18, 19, 20

Diagnosis and Treatment of Peptic Ulcer Disease

Initial Evaluation and Testing

The World Journal of Emergency Surgery recommends testing all patients with peptic ulcer disease for H. pylori infection before discharge, with preferred testing methods including urea breath test (UBT) with 88-95% sensitivity and 95-100% specificity, and stool antigen test with 94% sensitivity and 92% specificity 21, 22
The World Journal of Emergency Surgery suggests that endoscopic biopsy can also be used for H. pylori testing if endoscopy is performed 21, 22

H. pylori Eradication Regimens

The World Journal of Emergency Surgery recommends first-line therapy in areas with low clarithromycin resistance (<15%) as standard triple therapy for 14 days, including a proton pump inhibitor (PPI) standard dose twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily (or metronidazole 500 mg twice daily if penicillin allergy) 21, 22
The World Journal of Emergency Surgery suggests alternative therapy for high clarithromycin resistance areas, including sequential therapy for 10 days, with days 1-5 consisting of PPI twice daily and amoxicillin 1000 mg twice daily, and days 6-10 consisting of PPI twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily 21, 22

Management of Peptic Ulcer Disease: Evidence‑Based Recommendations

Overall Outcomes of Early Comprehensive Management

Immediate initiation of proton‑pump inhibitor (PPI) therapy, systematic testing and eradication of Helicobacter pylori when present, and discontinuation of NSAIDs/aspirin markedly lowers mortality to 8.6 % for bleeding ulcers and 23.5 % for perforated ulcers. 23

Risk Stratification and Need for Urgent Endoscopy

Patients presenting with hematemesis, melena, hemodynamic instability, severe abdominal pain suggestive of perforation, or persistent vomiting require urgent endoscopy; these high‑risk presentations are associated with the same mortality rates of 8.6 % (bleeding) and 23.5 % (perforation). 23, 24, 25

Pharmacologic Therapy for Bleeding Ulcers

After successful endoscopic hemostasis, an 80 mg intravenous PPI bolus followed by a continuous infusion of 8 mg/hour for 72 hours is recommended to reduce early re‑bleeding. 26

Helicobacter pylori Testing and Eradication

Diagnostic Testing

The urea breath test (sensitivity 88‑95 %, specificity 95‑100 %) and the stool antigen test (sensitivity 94 %, specificity 92 %) are the preferred non‑invasive methods for detecting active H. pylori infection in ulcer patients. 26, 27

First‑Line Eradication (Low Clarithromycin Resistance)

In regions where clarithromycin resistance is <15 %, a 14‑day standard triple therapy is advised:
Therapy should commence 72‑96 hours after starting intravenous PPI once oral intake is feasible. 26

Alternative Regimen (High Clarithromycin Resistance)

When resistance is high, a 10‑day sequential therapy is recommended, provided adherence can be ensured:

Second‑Line Therapy (Failure of First‑Line)

A 10‑day levofloxacin‑amoxicillin triple regimen is advised:

Surgical Management of Complicated Ulcers

Perforated peptic ulcers are the leading indication for emergency surgery and account for ≈ 40 % of all ulcer‑related deaths. 27, 28, 23
Successful surgical care hinges on prompt recognition, aggressive fluid resuscitation, appropriate antibiotic therapy, and timely operative intervention. 28, 24, 25

Need for Endoscopic Confirmation after H. pylori Eradication

Follow‑up Endoscopy Recommendations

Evidence‑Based Recommendations for Peptic Ulcer Disease Management

Acute Bleeding Management

High‑dose intravenous proton‑pump inhibitor (PPI) regimen – In patients with bleeding peptic ulcers who have high‑risk endoscopic stigmata after successful endoscopic hemostasis, an 80 mg IV PPI bolus followed by a continuous infusion of 8 mg/hour for 72 hours is recommended. 30

Helicobacter pylori Diagnostic Accuracy

Urea breath test (UBT) – Among adults with peptic ulcer disease, the UBT shows a sensitivity of 88‑95 % and a specificity of 95‑100 % for detecting H. pylori. 31
Stool antigen test – In the same population, stool antigen testing demonstrates a sensitivity of 94 % and a specificity of 92 % for H. pylori detection. 31
Endoscopic biopsy – When endoscopy is performed, biopsy‑based testing can be used for H. pylori diagnosis (no performance metrics provided). 31

First‑Line Eradication Regimens (Low Clarithromycin Resistance < 15‑20 %)

Standard triple therapy (14 days) – A 14‑day course of a standard‑dose PPI twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily (or metronidazole 500 mg twice daily if penicillin‑allergic) achieves eradication rates of 77‑90 % in regions with low clarithromycin resistance. [30][31]

Alternative First‑Line Regimens (High Clarithromycin Resistance > 20 %)

Sequential therapy (10 days) – For patients in whom clarithromycin resistance exceeds 20 %, a 10‑day sequential regimen is advised: days 1‑5 – PPI twice daily + amoxicillin 1000 mg twice daily; days 6‑10 – PPI twice daily + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily. [30][31]

Second‑Line Therapy (Failure of First‑Line Triple Therapy)

Levofloxacin‑amoxicillin triple therapy (10 days) – After unsuccessful standard triple therapy, a 10‑day regimen of a standard‑dose PPI twice daily, levofloxacin 500 mg once daily (or 250 mg twice daily), and amoxicillin 1000 mg twice daily is recommended without awaiting culture results. [30][31]